Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




NanoString Technologies to Accelerate Commercialization of Expression Profiling Products

By LabMedica International staff writers
Posted on 15 Jun 2009
NanoString Technologies (Seattle, WA, USA) will receive US$30 million equity financing, which will allow the company to accelerate commercialization of the nCounter analysis system for diagnostics and research. More...


The financing was lead by Clarus Ventures (Cambridge, MA, USA), a global life-sciences venture capital firm and joined by existing investors OVP Venture Partners (Seattle, WA, USA) and Draper Fisher Jurvetson (DFJ; Menlo Park, CA, USA).

The fully automated nCounter analysis system uses digital technology that enables direct multiplexed measurement of gene expression. It is sensitive and precise, and includes detection of fractional fold change differences. The technology uses molecular barcodes and single molecule imaging to detect and count hundreds of transcripts in a single reaction.

"The new funds will fuel our growth in manufacturing and product development and enhance our commercialization capabilities,” said Wayne Burns, CFO and acting CEO of NanoString Technologies.

NanoString Technologies is a life sciences tool company that has developed technology for creating molecular barcodes for tagging individual molecules in a biologic sample.

Related Links:
NanoString Technologies
Clarus Ventures
OVP Venture Partners
Draper Fisher Jurvetson



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.